Facebook

You are here: Home // Health

AbbVie Prices Hepatitis C Drug 12% Below Gilead Rival – Businessweek

Headlines & Global News AbbVie Prices Hepatitis C Drug 12% Below Gilead RivalBusinessweekAbbVie Inc. (ABBV:US) and Enanta Pharmaceuticals Inc. (ENTA:US)'s hepatitis C combination drug will be about 12 percent cheaper than its rival from Gilead Sciences Inc. (GILD:US), setting the stage for fierce competition for patients of the liver virus.AbbVie Wins Approval of Hepatitis C TreatmentNew... 

AstraZeneca cancer drug, companion test approved – SFGate

Pharmaceutical Business Review AstraZeneca cancer drug, companion test approvedSFGateTRENTON, N.J. (AP) — U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC. The drug is for women whose ovarian cancer is associated with …AstraZeneca Gets FDA Approval for Ovarian Cancer... 

Caramel apples linked to 5 deaths, Thurston County teen’s illness – The Seattle Times

The Seattle Times Caramel apples linked to 5 deaths, Thurston County teen's illnessThe Seattle TimesA teen boy from Thurston County is among some 28 people so far sickened in a multi-state outbreak of listeria food poisoning tied to prepackaged caramel-coated apples. By JoNel Aleccia. Seattle Times staff reporter. PREV of NEXT. Prepackaged caramel …Prepackaged Caramel Apples Linked... 

Roche Says Trials of Two Drugs Have Failed – New York Times

Wall Street Journal Roche Says Trials of Two Drugs Have FailedNew York TimesRoche, the Swiss drugmaker, suffered a double blow on Friday when two clinical drug studies failed, one for breast cancer and another for Alzheimer's disease, leading to the biggest percentage drop in its stock in five years. The company said it was ending a …Ahead of the Bell: ImmunoGen shares tumbleBusinessweekRoche... 

Roche Says Trials of Two Drugs Have Failed – New York Times

Wall Street Journal Roche Says Trials of Two Drugs Have FailedNew York TimesRoche, the Swiss drugmaker, suffered a double blow on Friday when two clinical drug studies failed, one for breast cancer and another for Alzheimer's disease, leading to the biggest percentage drop in its stock in five years. The company said it was ending a …Alzheimer's therapy flops in phase III clinical... 
© Copyright 2014 The Fresno News. All Rights Reserved.
Web Development by Sogware